Ryan Nipp: Olanzapine for Anorexia in Patients with Incurable Cancer and Cachexia
Ryan Nipp, Oncologist and Cancer Outcomes Researcher at the University of Oklahoma, shared a post on X about a paper he co-authored with colleagues published in JNCCN.
“Olanzapine for Anorexia in Patients with Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.”
Jill Feldman, Lung cancer Patient and Advocate, Co-Founder of EGFR Resisters, shared this post on X, adding:
“I really appreciate the focus on cachexia, an urgent and often overlooked unmet need, but I’d like to gently flag some language.
While anorexia-cachexia syndrome is a valid clinical term, anorexia alone can be confusing and distressing for patients, who hear or see the word in clinic notes.
In cancer, appetite loss and weight changes are typically part of cachexia, a complex metabolic syndrome driven by the cancer and treatment. Using clearer terms like cancer-associated cachexia or cancer-related appetite loss can help patients and families better understand what they’re experiencing.
The focus on supportive care is so critical and so needed – thank you!”
Title: Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial
Authors: Nada O. Othman, Hesham H. Abdel-Aal, Wessam A. Elsherief, Dina E. Farag, Catherine N. Hunter, and Samy A. Alsirafy
Read The Full Article at JNCCN.
More posts featuring Ryan Nipp.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023